PARP inhibitor or chemo plus immunotherapy after surgery for high-risk TNBC
Part of Cancer, Skin clinical trials.
This trial tests whether adding a PARP inhibitor or capecitabine (chemo) to a PD-1 inhibitor (immunotherapy) after surgery helps prevent triple-negative breast cancer from coming back. It's for people with high-risk disease who have completed initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with invasive breast cancer that is triple-negative (no estrogen, progesterone, or HER2 receptors).
- Your tumor stage must be T1c, N1-N2 or T2, N0-N2 or T3, N0-N2 or T4a-d, N0-N2 (your doctor will confirm this).
- Your general health must be good: normal blood counts, liver and kidney function, and heart function.
- You cannot have had chemotherapy or radiation for any other cancer before (except for certain very early-stage cancers).
- You must agree to use effective birth control if you could become pregnant, and you cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving more of the immunotherapy drug pembrolizumab (Keytruda) after surgery helps people with early-stage triple-negative breast cancer that did not completely disappear with the initial chemotherapy plus immunotherapy. This is for patients who still have some cancer left after surgery, to reduce the chance of it coming back.
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
This trial tests two different sequences of chemotherapy combined with pembrolizumab (an immunotherapy drug) given before surgery for high-risk triple-negative breast cancer. The goal is to see which sequence works better at shrinking or eliminating the tumor.
This trial looks at different ways to use the chemotherapy drug capecitabine for people with triple-negative breast cancer who still have cancer cells after initial treatment and surgery. It aims to find the best approach to improve outcomes.
This trial tests if combining the chemotherapy pill capecitabine with the immunotherapy drug camrelizumab can help people with triple-negative breast cancer (TNBC) who still have tumor tissue after initial treatment. It is for patients whose breast cancer has structures called tumor-associated lymphoid structures (TLS) and who did not achieve a complete response to neoadjuvant therapy.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.